Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.36 |
| ▸ | NT5E | P21589 | 10/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19979255 | 0.87 | PDE2A (0.37) | PDE2ANT5EALDH1A1LMNATP53 | |
| SCHEMBL19979256 | 0.85 | NT5E (0.39) | PDE2ANT5EALDH1A1LMNATP53 | |
| SCHEMBL19975506 | 0.85 | NT5E (0.39) | PDE2ANT5EALDH1A1LMNATP53 | |
| SCHEMBL19979002 | 0.81 | PDE2A (0.33) | PDE2ANT5EALDH1A1LMNATP53 | |
| SCHEMBL19975504 | 0.76 | NT5E (0.39) | PDE2ANT5EALDH1A1LMNATP53 | |
| SCHEMBL19979067 | 0.74 | LMNA (0.40) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL19974569 | 0.72 | ADORA2A (0.41) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL19974567 | 0.71 | TBXAS1 (0.37) | NT5EALDH1A1MAPTTDP1TBXAS1 | |
| SCHEMBL22700325 | 0.70 | LMNA (0.42) | PDE2ANT5EALDH1A1LMNATP53 | |
| SCHEMBL19974597 | 0.69 | NT5E (0.36) | NT5ETDP1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512860-B1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC (CA) | 2020-11-25 | — | — | EP | disclosed |